Cargando…
Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy
BACKGROUND: Multiple sclerosis (MS) patients with breakthrough disease on immunomodulatory drugs are frequently offered to switch to natalizumab or immunosuppressants. The effect of natalizumab monotherapy in patients with breakthrough disease is unknown. METHODS: This is an open-label retrospective...
Autores principales: | Castillo-Trivino, Tamara, Mowry, Ellen M., Gajofatto, Alberto, Chabas, Dorothee, Crabtree-Hartman, Elizabeth, Cree, Bruce A., Goodin, Douglas S., Green, Ari J., Okuda, Darin T., Pelletier, Daniel, Zamvil, Scott S., Vittinghoff, Eric, Waubant, Emmanuelle |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033401/ https://www.ncbi.nlm.nih.gov/pubmed/21304907 http://dx.doi.org/10.1371/journal.pone.0016664 |
Ejemplares similares
-
Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review
por: Castillo-Trivino, Tamara, et al.
Publicado: (2013) -
Clinical predictors of early second event in patients with clinically isolated syndrome
por: Mowry, Ellen M., et al.
Publicado: (2009) -
A randomized controlled phase II trial of riluzole in early multiple sclerosis
por: Waubant, Emmanuelle, et al.
Publicado: (2014) -
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
por: Spencer, Collin M., et al.
Publicado: (2015) -
Long‐term evolution of multiple sclerosis disability in the treatment era
por: Cree, Bruce A. C., et al.
Publicado: (2016)